TimesSquare Capital Management LLC Boosts Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS)

TimesSquare Capital Management LLC raised its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 250.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 895,574 shares of the company’s stock after buying an additional 640,329 shares during the quarter. TimesSquare Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $23,016,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NAMS. Geode Capital Management LLC boosted its holdings in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after acquiring an additional 1,399 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in NewAmsterdam Pharma in the fourth quarter worth about $80,000. Quarry LP boosted its holdings in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after acquiring an additional 6,247 shares in the last quarter. Barclays PLC boosted its holdings in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares in the last quarter. Finally, Bellevue Group AG acquired a new stake in NewAmsterdam Pharma in the third quarter worth about $128,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29. Following the completion of the transaction, the insider now directly owns 11,150,461 shares of the company’s stock, valued at approximately $283,110,204.79. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 404,927 shares of company stock valued at $10,390,787. 19.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank lifted their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $41.60.

NewAmsterdam Pharma Stock Down 4.6 %

NewAmsterdam Pharma stock opened at $19.12 on Thursday. NewAmsterdam Pharma has a 52 week low of $15.19 and a 52 week high of $27.29. The stock has a 50-day moving average price of $23.42 and a 200 day moving average price of $20.17.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.